艾司氯胺酮鼻喷雾剂上市近五年真实世界安全性分析
该研究基于美国艾司氯胺酮REMS项目患者监测表及Janssen US-GMS数据库58个月数据,描述真实世界安全性。共58,483例患者完成1,486,213次门诊治疗,镇静、分离和血压升高分别见于34.7%、41.0%和0.9%的治疗次数,严重不良事件报告率低,自杀率低于背景水平,未发现新安全信号。
要点
- 真实世界中镇静和分离反应较常见,血压升高报告率低。
- 近5年真实世界安全性数据与临床研究及产品标签一致。
核心结论
- 美国近5年艾司氯胺酮真实世界使用未发现新的安全信号,与临床研究和现行产品标签的安全性特征一致。
研究设计与样本
- 基于美国艾司氯胺酮REMS项目患者监测表及Janssen US-GMS数据库2019年3月5日至2024年1月5日的数据进行描述性分析。
主要发现
- 58,483例患者完成1,486,213次门诊治疗,大多数患者年龄26-55岁(64.3%)且为女性(61.1%)。
- 镇静、分离和血压升高分别报告于34.7%、41.0%和0.9%的治疗次数。
- REMS和US-GMS中严重不良事件分别报告于不足0.1%和0.18%的治疗次数,自杀率低于背景水平,报告210例全因滥用/误用。
关键数值与推荐
- 镇静报告率34.7%,分离报告率41.0%,血压升高报告率0.9%,均以治疗次数为分母。
- 严重不良事件报告率在REMS中不足0.1%、在US-GMS中为0.18%。
- 全因滥用/误用报告210例。
临床怎么用
- 真实世界数据支持艾司氯胺酮现有安全性特征,临床仍需关注镇静、分离和血压升高等常见反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to comprehensively examine the real-world safety of esketamine using 58 months of postapproval data in the United States. METHODS: U.S. safety data from patient monitoring forms submitted to the esketamine Risk Evaluation and Mitigation Strategy (REMS) program and reports submitted to the Janssen U.S. Global Medical Safety (US-GMS) database were evaluated (March 5, 2019, to January 5, 2024). Patient characteristics, use and dosage patterns, adverse events of interest (actively solicited reports of sedation, dissociation, and increased blood pressure), and serious adverse events following esketamine administration were described. The incidence of suicidality and drug abuse/misuse was also evaluated. RESULTS: Most patients were 26-55 years of age (64.3%) and female (61.1%). A total of 1,486,213 outpatient treatment sessions were completed by 58,483 patients who had at least one esketamine treatment session. Sedation, dissociation, and increased blood pressure were reported in 34.7%, 41.0%, and 0.9% of sessions, respectively. Serious adverse events were reported in <0.1% and 0.18% of treatment sessions in REMS and US-GMS, respectively; suicide rates were lower than background rates; and 210 incidences of all-cause abuse/misuse were reported. CONCLUSIONS: Analysis of almost 5 years of real-world use of esketamine in the United States remains consistent with the established safety profile from clinical studies and current product labeling. No new safety signals were identified.
引用
- Sanacora G, Ahmed M, Brown B, et al. Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval. Am J Psychiatry. 2025. PMID: 40926574. doi:10.1176/appi.ajp.20240655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。